[go: up one dir, main page]

BR0314212A - Projeto de análogos de quimiocina para o tratamento de doenças humanas - Google Patents

Projeto de análogos de quimiocina para o tratamento de doenças humanas

Info

Publication number
BR0314212A
BR0314212A BR0314212-4A BR0314212A BR0314212A BR 0314212 A BR0314212 A BR 0314212A BR 0314212 A BR0314212 A BR 0314212A BR 0314212 A BR0314212 A BR 0314212A
Authority
BR
Brazil
Prior art keywords
analogs
treatment
chemokine
human diseases
project
Prior art date
Application number
BR0314212-4A
Other languages
English (en)
Other versions
BR0314212C1 (pt
Inventor
Ahmed Merzouk
Donald Wong
Hassan Salari
Original Assignee
Chemokine Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemokine Therapeutics Corp filed Critical Chemokine Therapeutics Corp
Publication of BR0314212A publication Critical patent/BR0314212A/pt
Publication of BR0314212C1 publication Critical patent/BR0314212C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PROJETO DE ANáLOGOS DE QUIMIOCINA PARA O TRATAMENTO DE DOENCAS HUMANAS". A presente invenção se refere aos análogos de quimiocina, incluindo análogos IL-8, análogos IP-10, análogos MIP-l<244>, análogos RANTES, análogos I-309, análogos MCP-1 e análogos CCL28 que são úteis para o tratamento de várias doenças e transtornos e como um coadjuvante no tratamento de uma variedade de doenças e transtornos. Uma quantidade terapeuticamente eficaz do análogo de quimiocina pode ser administrada ao paciente que necessite de tal tratamento.
BRC10314212-4A 2002-09-13 2003-09-11 projeto de análogos a quimiocina de proteìna-10 (ip-10 ou cxcl10) induzìveis por interferon para o tratamento de doenças humanas BR0314212C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/243,795 US7091310B2 (en) 2002-09-13 2002-09-13 Chemokine analogs for the treatment of human disease
PCT/US2003/028745 WO2004024088A2 (en) 2002-09-13 2003-09-11 Design of chemokine analogs for the treatment of human diseases

Publications (2)

Publication Number Publication Date
BR0314212A true BR0314212A (pt) 2005-07-19
BR0314212C1 BR0314212C1 (pt) 2008-03-11

Family

ID=31991735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRC10314212-4A BR0314212C1 (pt) 2002-09-13 2003-09-11 projeto de análogos a quimiocina de proteìna-10 (ip-10 ou cxcl10) induzìveis por interferon para o tratamento de doenças humanas

Country Status (6)

Country Link
US (2) US7091310B2 (pt)
EP (2) EP1536834A4 (pt)
JP (2) JP2005539063A (pt)
BR (1) BR0314212C1 (pt)
CA (1) CA2498723A1 (pt)
WO (1) WO2004024088A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US20060233748A1 (en) * 2002-09-13 2006-10-19 Ahmed Merzouk Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
CA2596232A1 (en) 2005-01-31 2006-08-03 Effector Cell Institute The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment
WO2007036036A1 (en) * 2005-09-29 2007-04-05 British Columbia Cancer Agency Branch Method and composition for increasing the engraftment efficiency of stem cells
CA2627939A1 (en) * 2005-12-15 2007-06-21 Laboratoires Serono S.A. New chemokine antagonists
WO2007079460A2 (en) * 2006-01-04 2007-07-12 Chemokine Therapeutics Corporation Design of cxc chemokine analogs for the treatment of human diseases
EP2089426B1 (en) * 2006-06-20 2016-04-20 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Antimicrobial kinocidin compositions and methods of use
EP1882698A1 (en) * 2006-07-26 2008-01-30 Chemokine Therapeutics Corp. Design of interferon-inducible protein-10 (IP10 or CXCL10) chemokine analogs for the treatment of human diseases
JP2008031143A (ja) * 2006-07-26 2008-02-14 Chemokine Therapeutics Corp ヒト疾患を治療するためのインターフェロン誘導性タンパク質−１０（ｉｐ−１０又はｃｘｃｌ１０）ケモカイン類縁体の設計
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
EP2262531A1 (en) * 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2011011733A2 (en) 2009-07-24 2011-01-27 The Regents Of The University Of Michigan Factor replacement therapy
EP3247382B1 (en) 2015-01-22 2020-05-06 Ram, Isanaka Peptide for treating inflammatory diseases
US20210300981A1 (en) * 2018-07-24 2021-09-30 University Of Virginia Patent Foundation Compositions and methods for combating multidrug-resistant bacteria
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2023213400A1 (en) * 2022-05-05 2023-11-09 Institute For Research In Biomedicine Antibodies against chemokines, method for identifying said antibodies and uses thereof
WO2024251939A2 (en) * 2023-06-09 2024-12-12 Université De Genève Ccr1 modulators and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401651A (en) * 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
AU3078892A (en) * 1991-12-04 1993-06-28 Biomedical Research Centre Limited, The Human interleukin-8 analogs
AU3460295A (en) * 1994-06-20 1996-01-15 Chiron Corporation Polypeptides with interleukin 8 receptor 1 (il8r1) binding domains
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6762341B2 (en) * 2000-02-10 2004-07-13 Schering Corporation Uses of mammalian CCR8 receptors and related reagents
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20060233748A1 (en) * 2002-09-13 2006-10-19 Ahmed Merzouk Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
ATE265219T1 (de) 2000-05-09 2004-05-15 Univ British Columbia Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CN1249078C (zh) * 2000-11-27 2006-04-05 Rmf迪克塔吉恩有限公司 对化学合成多肽进行折叠的方法
US20030004136A1 (en) * 2001-03-05 2003-01-02 Geeta Saxena IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US6515001B2 (en) * 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US6693134B2 (en) * 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
US20030092674A1 (en) * 2001-06-14 2003-05-15 Geeta Saxena Tricyclic rantes receptor ligands
US6831101B2 (en) * 2001-06-14 2004-12-14 Chemokine Therapeutics Corporation Tricyclic rantes receptor ligands

Also Published As

Publication number Publication date
US20040197303A1 (en) 2004-10-07
US7091310B2 (en) 2006-08-15
CA2498723A1 (en) 2004-03-25
EP1536834A2 (en) 2005-06-08
EP1834961A3 (en) 2008-06-11
EP1834961A2 (en) 2007-09-19
WO2004024088A2 (en) 2004-03-25
JP2005539063A (ja) 2005-12-22
BR0314212C1 (pt) 2008-03-11
JP2007106768A (ja) 2007-04-26
US20070066523A1 (en) 2007-03-22
EP1536834A4 (en) 2007-11-07
WO2004024088A3 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
BR0314212A (pt) Projeto de análogos de quimiocina para o tratamento de doenças humanas
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
PT1448564E (pt) Composto do tipo indolizina substituidos e metodos de utilizacao
GB9902453D0 (en) Chemical compounds
DE60220887D1 (de) Agonisten von beta-adrenorezeptoren
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
EP1689713A4 (en) BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
ATE516366T1 (de) Regulierte aptamer-therapeutika
ECSP024244A (es) Uso de (z)-2-cyano-3-hydroxy-but-2-enoic acid(4´-trifluoromethylphenyl)-amide para el tratamiento de la esclerosis múltiple
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
BRPI0508927A (pt) compostos úteis para o tratamento de doenças
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen
UY26179A1 (es) Amidas sustituidas del ácido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporación de adenosina.
EP1912963A4 (en) CYCLIC KETALS AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
FI982198A0 (fi) IL-muteiini
NO20062316L (no) Nye CXCL8 antagonister

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR S CERTIFICATE:

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing

Free format text: ADDITIONAL INVENTOR S CERTIFICATE:

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.

B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired

Free format text: ADDITIONAL INVENTOR S CERTIFICATE: